mRNA-1405 / Moderna - LARVOL DELTA

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (clinicaltrials.gov) - P1/2 | N=1285 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (clinicaltrials.gov) - P1/2 | N=1285 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Apr 2025 ➔ Nov 2025

Trial completion date • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (clinicaltrials.gov) - P1/2 | N=1285 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (clinicaltrials.gov) - P1/2 | N=1260 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | Phase classification: P1 ➔ P1/2 | N=664 ➔ 1260 | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age. (clinicaltrials.gov) - P1 | N=664 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: May 2025 ➔ Dec 2024

Trial completion date • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age. (clinicaltrials.gov) - P1 | N=660 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age. (clinicaltrials.gov) - P1 | N=660 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2025 ➔ May 2025

Enrollment open • Trial completion date • Gastroenterology • Gastrointestinal Disorder

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age. (clinicaltrials.gov) - P1 | N=660 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1 trial • Gastroenterology • Gastrointestinal Disorder